Director/PDMR Shareholding

RNS Number : 9810G

e-Therapeutics plc

02 June 2017

 

E-THERAPEUTICS PLC

("e-Therapeutics" or the "Company")

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS

DISCHARGING MANAGERIAL RESPONSIBILITIES

Oxford, UK, 2 June 2017 - e-Therapeutics plc (AIM: ETX), the drug discovery company, announces that it has today received notifications from three of its directors that they have purchased, in aggregate, 2,830,000 shares in the Company at a price of 6 pence per share. The purchases took place on 1 June 2017.

The number of ordinary shares purchased by each director is set out below:          

Director	Number of shares purchased
Iain Ross	1,000,000
Ray Barlow	830,000
Steve Medlicott	1,000,000

Following these trades, the interests of those directors in ordinary shares of ETX are as follows:

Director	Number of shares held	Percentage of issued share capital
Iain Ross	1,000,000	0.37%
Ray Barlow	830,000	0.31%
Steve Medlicott	1,250,000	0.47%

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further details:

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Iain Ross
2	Reason for the notification
a)	Position/status	Non-Executive Chairman
b)	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	e-Therapeutics plc
b)	LEI	21380049RHSSJXWKYT18
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 0.1 pence ISIN:   GB00B2823H99
b)	Nature of the transaction	Purchase of shares
c)	Price(s) and volume(s)	1,000,000 ordinary shares at a price of 6 pence per share
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	1 June 2017
f)	Place of the transaction	London Stock Exchange, AIM (XLON)

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Ray Barlow
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	e-Therapeutics plc
b)	LEI	21380049RHSSJXWKYT18
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 0.1 pence ISIN:   GB00B2823H99
b)	Nature of the transaction	Purchase of shares
c)	Price(s) and volume(s)	830,000 ordinary shares at a price of 6 pence per share
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	1 June 2017
f)	Place of the transaction	London Stock Exchange, AIM (XLON)

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Steve Medlicott
2	Reason for the notification
a)	Position/status	Finance Director
b)	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	e-Therapeutics plc
b)	LEI	21380049RHSSJXWKYT18
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 0.1 pence ISIN:   GB00B2823H99
b)	Nature of the transaction	Purchase of shares
c)	Price(s) and volume(s)	1,000,000 ordinary shares at a price of 6 pence per share
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	1 June 2017
f)	Place of the transaction	London Stock Exchange, AIM (XLON)

For further information, please contact:

Contacts:

e-Therapeutics plc Iain Ross, Chairman Steve Medlicott, Finance Director	Tel: [phone] www.etherapeutics.co.uk
Numis Securities Limited Michael Meade / Freddie Barnfield (Corporate Finance) James Black (Corporate Broking)	Tel: [phone] www.numis.com
Instinctif Partners Melanie Toyne Sewell / Alex Shaw	Tel: [phone] Email: [e-mail]

About e-Therapeutics plc

e-Therapeutics is a drug discovery company with a unique and proprietary in silico discovery platform.  The Company is applying its computational platform to the discovery of new drug candidates for which it can secure robust intellectual property rights.

The therapeutic focus of the Company's discovery activity is in areas of complex disease with unmet medical need, including immuno-oncology.  The business model is to partner these preclinical drug candidates.

e-Therapeutics is headquartered in Oxford. For more information about the Company please visit www.etherapeutics.co.uk.

 

END

 

 

DSHLIFVDRDIFIID